VICP — Vicapsys Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00- $57.30m
- $57.79m
- 15
- 58
- 58
- 40
Annual balance sheet for Vicapsys Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.264 | 0.001 | 0.217 | 0.014 | 0.009 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.264 | 0.001 | 0.223 | 0.072 | 0.04 |
| Net Intangible Assets | |||||
| Total Assets | 0.698 | 0.404 | 0.594 | 0.072 | 0.04 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.396 | 0.853 | 0.716 | 1.02 | 1.97 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.396 | 0.853 | 0.716 | 1.02 | 1.97 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 0.302 | -0.449 | -0.122 | -0.951 | -1.93 |
| Total Liabilities & Shareholders' Equity | 0.698 | 0.404 | 0.594 | 0.072 | 0.04 |
| Total Common Shares Outstanding |